Lupin launches Tadalafil Tablets USP
Deepthi | Myequity news | Date : 12-02-2019 14:48:00 IST
Pharma major Lupin announced the launch of Tadalafil Tablets USP 20mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Tadalafil Tablets USP 20mg is the generic equivalent of Eli Lilly’s Adcirca Tablets 20mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group) to improve exercise ability.
Tadalafil Tablets, 20mg (RLD: Adcirca) had annual sales of approximately US$474.3 million in the US (IQVIA MAT December 2018).
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.